ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Fibrocell, Castle Creek Enter Collaboration
April 16, 2019To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)... -
Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
February 24, 2019Phoenix Tissue Repair, Inc., a biotechnology company focused on developing transformational disease-modifying treatments for dystrophic epidermolysis bullosa (DEB), today announced that the first patient has been dosed in the Phase 1/2, first in-human tri -
Constant Pharmaceuticals to Initiate Clinical Development of TXA127
November 29, 2018Constant Pharmaceuticals plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with.....
Pharma Sources Insight January 2025
